Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease

Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis

(2019) Antoine Leuzy et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Added value of 18 F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study

(2018) Mathieu Ceccaldi et al.   Alzheimers & Dementia

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease

(2018) Clifford R. Jack et al.   Alzheimers & Dementia

A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer’s Disease

(2018) Enrico R. Fantoni et al.   JOURNAL OF ALZHEIMERS DISEASE

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort

(2018) Arno de Wilde et al.   JAMA Neurology

Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease

(2018) Lisa M. Bloudek et al.   JOURNAL OF ALZHEIMERS DISEASE

Risk of Alzheimer's Disease Biological Misdiagnosis Linked to Cerebrospinal Collection Tubes

(2018) Armand Perret-Liaudet et al.   JOURNAL OF ALZHEIMERS DISEASE

Additional Use of Aβ42/Aβ40 Ratio with Cerebrospinal Fluid Biomarkers P-Tau and Aβ42 Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice

(2018) Mathilde Sauvée et al.   JOURNAL OF ALZHEIMERS DISEASE

AMYPAD Diagnostic and Patient Management Study: Rationale and design

(2018) Giovanni B. Frisoni et al.   Alzheimers & Dementia

Clinical Use and Utility of Amyloid Imaging

(2017) Henryk Barthel et al.   JOURNAL OF NUCLEAR MEDICINE

Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers

(2017) Giovanni B Frisoni et al.   LANCET NEUROLOGY

Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

(2017) Konstantinos Chiotis et al.   NEUROBIOLOGY OF AGING

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

(2017) Piotr Lewczuk et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?

(2016) Philip S.J. Weston et al.   JOURNAL OF ALZHEIMERS DISEASE

Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers

(2016) Mohamed Reda Bensaïdane et al.   JOURNAL OF ALZHEIMERS DISEASE

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

(2015) Osama Sabri et al.   Alzheimers & Dementia

Prevalence of Amyloid PET Positivity in Dementia Syndromes

(2015) Rik Ossenkoppele et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?

(2015) Marina Boccardi et al.   Neurodegenerative Diseases

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease

(2015) Sebastian Palmqvist et al.   NEUROLOGY

Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques

(2015) Sarah E. Monsell et al.   JAMA Neurology

DIAGNOSTIC VALUE OF AMYLOID IMAGING IN EARLY ONSET DEMENTIA

(2014) Marissa Deborah Zwan et al.   Alzheimers & Dementia

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline

(2012) Michael Grundman et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Impact of molecular imaging on the diagnostic process in a memory clinic

(2012) Rik Ossenkoppele et al.   Alzheimers & Dementia

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study

(2012) Christopher M Clark et al.   LANCET NEUROLOGY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study

(2011) Henryk Barthel et al.   LANCET NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION